Asterias Biotherapeutics Inc. Common Series A is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. The stock will provide you with a reasonable dividend income. Asterias Biotherapeutics Inc. Common Series A is not very popular among insiders. Tradey thinks it is not wise to invest in Asterias Biotherapeutics Inc. Common Series A.